dr. sosman on the mechanism of action of ipilimumab in melanoma
Published 10 years ago • 2.4K plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:36
dr. sosman on 3 mg/kg ipilimumab vs 10 mg/kg ipilimumab in metastatic melanoma
-
1:40
dr. jeff sosman discusses immunotherapy in melanoma and renal cancer
-
2:48
dr. sosman on drug sequencing in melanoma
-
1:17
dr. shoushtari on the role of nivolumab and ipilimumab in mucosal melanoma
-
3:24
ipilimumab side effect management in melanoma
-
1:51
dr. sosman discusses immunotherapies in melanoma or renal cancer
-
1:47
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma
-
49:05
pediatric autoimmune encephalitis – catherine otten, md
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
5:00
adjuvant therapy for stage iii melanoma
-
1:28
dr. jeffery s. weber on sequencing of nivolumab, ipilimumab in metastatic melanoma
-
1:10
dr. ribas on the efficacy of ipilimumab in melanoma
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
29:39
history of melanoma immunotherapy - from freund to ipilimumab
-
4:25
the phenomenon of immunotherapy in melanoma
-
1:45
dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab
-
1:59
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma
-
35:43
immunotherapy: yervoy and beyond
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma